{
    "symbol": "RIGL",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-03 01:06:06",
    "content": " Mutations in IDH1 are seen in around 6% to 16% of AML patients and although this is a small population of AML patients, they are very well defined based on standard widespread testing that is done upon diagnosis and prior to initiation of a new line of treatment. But fortunately, it happened only 14% of these patients and the most - and about half of these were Grade 1 or Grade 2, the others were Grade 3 or Grade 4, 8% total, only three patients, however, discontinued treatment because of the differentiation of syndrome, meaning the great majority of these are very - they can be managed well with treatment interruptions. Please proceed with your question. Please proceed with your question. Yes, there you go. Yes, there you go. Please proceed with your question. Please proceed with your question. I think this is a drug that - of course, you start starting it in refractory relapse as the nature of drug development in AML, but it has a lot of potential for frontline, both as a single agent and in combination because there's patients where you're aiming for different things. Please proceed with your question. Please proceed with your question."
}